雜志介紹

Clinical Lung Cancer雜志介紹

《Clinical Lung Cancer》是一本以English為主的未開放獲取國際優(yōu)秀期刊，中文名稱臨床肺癌，本刊主要出版、報道醫(yī)學(xué)-ONCOLOGY領(lǐng)域的研究動態(tài)以及在該領(lǐng)域取得的各方面的經(jīng)驗和科研成果，介紹該領(lǐng)域有關(guān)本專業(yè)的最新進(jìn)展，探討行業(yè)發(fā)展的思路和方法，以促進(jìn)學(xué)術(shù)信息交流，提高行業(yè)發(fā)展。該刊已被國際權(quán)威數(shù)據(jù)庫SCIE收錄，為該領(lǐng)域相關(guān)學(xué)科的發(fā)展起到了良好的推動作用，也得到了本專業(yè)人員的廣泛認(rèn)可。該刊最新影響因子為3.3，最新CiteScore 指數(shù)為7。

本刊近期中國學(xué)者發(fā)表的論文主要有：

• Pathological Stage N1 Limited-Stage Small-Cell Lung Cancer Patients Can Benefit From Surgical Resection

  Author: Yu, Lian; Xu, Jianlin; Qiao, Rong; Han, Baohui; Zhong, Hua; Zhong, Runbo

• The comparison of Lobe-Specific or Systematic Mediastinal Lymph Node Dissection for Early-Stage Lung Adenocarcinoma With Consolidation Tumor Ratio Over 0.5

  Author: Sui, Qihai; Yang, Huiqiang; Yin, Jiacheng; Li, Ming; Jin, Xing; Chen, Zhencong; Jiang, Wei; Wang, Qun

• The Value of Radiotherapy in Patients With Resectable Stage IIIA Non-Small-Cell Lung Cancer in the Era of Individualized Treatment: A Population-Based Analysis

  Author: Liu, Bohao; Wang, Zhiyu; Zhao, Heng; Gao, Shan; Wang, Hongyi; Zhang, Yanpeng; Fan, Kun; Tao, Runyi; Li, Yixing; Feng, Jinteng; Sun, Yuchen; Zhang, Jia; Zhang, Guangjian

• Impact of TP53 Mutations on EGFR-Tyrosine Kinase Inhibitor Efficacy and Potential Treatment Strategy

  Author: Fu, Jing; Tong, Yuyang; Xu, Ziguang; Li, Yaonan; Zhao, Ya; Wang, Tao; Li, Cuidan; Cang, Shundong

英文介紹

Clinical Lung Cancer雜志英文介紹

Clinical Lung Cancer is a peer-reviewed bimonthly journal that publishes original articles describing various aspects of clinical and translational research of lung cancer. Clinical Lung Cancer is devoted to articles on detection, diagnosis, prevention, and treatment of lung cancer. The main emphasis is on recent scientific developments in all areas related to lung cancer. Specific areas of interest include clinical research and mechanistic approaches; drug sensitivity and resistance; gene and antisense therapy; pathology, markers, and prognostic indicators; chemoprevention strategies; multimodality therapy; and integration of various approaches.